Form 8-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2011

 

 

CYTRX CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

(State or Other Jurisdiction

of Incorporation)

 

000-15327   58-1642740

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

11726 San Vicente Boulevard, Suite 650

Los Angeles, California

  90049
(Address of Principal Executive Offices)   (Zip Code)

(310) 826-5648

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (See General Instruction A.2 below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events

On August 1, 2011, Cytrx Corporation issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

- 2 -


Item 9.01 Exhibits

 

(d) Exhibits

There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

 

- 3 -


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 1, 2011   By:  

/s/ JOHN Y. CALOZ

    John Y. Caloz
    Chief Financial Officer

 

- 4 -


Index to Exhibits

 

Exhibit
No.

  

Description

99.1    Press release of CytRx Corporation issued August 1, 2011

 

- 5 -